Arcturus has two proprietary technologies that have the potential to solve the major hurdles in RNA medicine development. Our LUNAR™ lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology can be used together or separately to create the next-generation of safe, effective RNA medicines.
LUNAR allows systemic delivery of all types of RNA therapeutics to target tissues. UNA oligomers are more stable, more potent and less toxic than standard oligomers.
We use our technologies in house, and partner with industry leaders, to discover and develop RNA medicines that treat rare and orphan diseases.
February 12, 2018
Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of Research and Development
February 2, 2018
Arcturus Therapeutics Appoints Mark Herbert as Interim President
January 4, 2018
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics